1. Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism: clinical and experimental. 2019;92:6-10. [DOI:10.1016/j.metabol.2018.09.005]

2. Boutari C, Mantzoros CS. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism: clinical and experimental. 2022;133:155217. [DOI:10.1016/j.metabol.2022.155217]

3. Tutunchi H, Naeini F, Ebrahimi-Mameghani M, Mobasseri M, Naghshi S. The association of the steatosis severity, NAFLD fibrosis score and FIB-4 index with atherogenic dyslipidaemia in adult patients with NAFLD: A cross-sectional study. 2021;75(6):e14131. [DOI:10.1111/ijcp.14131]

4. Ugwuja E, Ogbonna N, Nwibo A, Onimawo I. Overweight and Obesity, Lipid Profile and Atherogenic Indices among Civil Servants in Abakaliki, South Eastern Nigeria. Annals of medical and health sciences research. 2013;3(1):13-8. [DOI:10.4103/2141-9248.109462]

5. Bora K, Pathak MS, Borah P, Hussain MI, Das D. Association of the Apolipoprotein A-I Gene Polymorphisms with Cardiovascular Disease Risk Factors and Atherogenic Indices in Patients from Assam, Northeast India. Balkan journal of medical genetics : BJMG. 2017;20(1):59-70. [DOI:10.1515/bjmg-2017-0002]

6. Cai G, Shi G, Xue S, Lu W. The atherogenic index of plasma is a strong and independent predictor for coronary artery disease in the Chinese Han population. Medicine. 2017;96(37):e8058. [DOI:10.1097/MD.0000000000008058]

7. Fasanmade OA, Odeniyi IA, Amira CO, Okubadejo NU. Association of body mass index and abdominal adiposity with atherogenic lipid profile in Nigerians with type 2 diabetes and/or hypertension. Nigerian medical journal : journal of the Nigeria Medical Association. 2013;54(6):402-7. [DOI:10.4103/0300-1652.126296]

8. Hussain A, Alam JM. Dyslipidaemia in woman with polycystic ovarian syndrome: a case control study in tertiary care hospital of Karachi. JPMA The Journal of the Pakistan Medical Association. 2014;64(9):1049-52.

9. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arteriosclerosis, thrombosis, and vascular biology. 2006;26(5):968-76. [DOI:10.1161/01.ATV.0000216787.85457.f3]

10. Zeller M, Steg PG, Ravisy J, Lorgis L, Laurent Y, Sicard P, et al. Relation between body mass index, waist circumference, and death after acute myocardial infarction. Circulation. 2008;118(5):482-90. [DOI:10.1161/CIRCULATIONAHA.107.753483]

11. Al-Goblan AS, Al-Alfi MA, Khan MZ. Mechanism linking diabetes mellitus and obesity. Diabetes, metabolic syndrome and obesity : targets and therapy. 2014;7:587-91. [DOI:10.2147/DMSO.S67400]

12. Narkiewicz K. Obesity and hypertension--the issue is more complex than we thought. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2006;21(2):264-7. [DOI:10.1093/ndt/gfi290]

13. Bays HE, Toth PP, Kris-Etherton PM, Abate N, Aronne LJ, Brown WV, et al. Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association. Journal of clinical lipidology. 2013;7(4):304-83. [DOI:10.1016/j.jacl.2013.04.001]

14. Rashid S, Genest J. Effect of obesity on high-density lipoprotein metabolism. Obesity (Silver Spring, Md). 2007;15(12):2875-88. [DOI:10.1038/oby.2007.342]

15. Woudberg NJ, Lecour S, Goedecke JH. HDL Subclass Distribution Shifts with Increasing Central Adiposity. 2019;2019:2107178. [DOI:10.1155/2019/2107178]

16. Wang H, Peng DQ. New insights into the mechanism of low high-density lipoprotein cholesterol in obesity. Lipids in health and disease. 2011;10:176. [DOI:10.1186/1476-511X-10-176]

17. Kirkpatrick CF, Sikand G, Petersen KS, Anderson CAM, Aspry KE, Bolick JP, et al. Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association. Journal of clinical lipidology. 2023;17(4):428-51. [DOI:10.1016/j.jacl.2023.05.099]

18. Ostrowska L, Witczak K, Adamska E. Effect of nutrition and atherogenic index on the occurrence and intensity of insulin resistance. Polskie Archiwum Medycyny Wewnetrznej. 2013;123(6):289-96. [DOI:10.20452/pamw.1774]

19. Whaley MH, Brubaker PH, Otto RM. ACSM's. Guidelines for Exercise Testing and Prescription. Baltimore: Lippincott Williams and Wilkins; 2005.

20. Giada Mde L. Food applications for flaxseed and its components: products and processing. Recent patents on food, nutrition & agriculture. 2010;2(3):181-6. [DOI:10.2174/1876142911002030181]

21. Ahmed DH, Fateh HL. Impact of flaxseed supplementation on lipid profile and liver enzymes in patients with non-alcoholic fatty liver disease: Systematic review and meta-analysis of randomized controlled trials. Prostaglandins & other lipid mediators. 2024;173:106838. [DOI:10.1016/j.prostaglandins.2024.106838]

22. Roohbakhsh A, Parhiz H, Soltani F, Rezaee R, Iranshahi M. Molecular mechanisms behind the biological effects of hesperidin and hesperetin for the prevention of cancer and cardiovascular diseases. Life sciences. 2015;124:64-74. [DOI:10.1016/j.lfs.2014.12.030]

23. Shylaja H, Viswanatha GL. Effect of hesperidin on blood pressure and lipid profile: A systematic review and meta-analysis of randomized controlled trials. 2024;38(5):2560-71. [DOI:10.1002/ptr.8174]

24. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical chemistry. 1972;18(6):499-502. [DOI:10.1093/clinchem/18.6.499]

25. Tecer D, Sunar I, Ozdemirel AE, Tural R, Kucuksahin O, Sepici Dincel A, et al. Usefullnes of atherogenic indices and Ca-LDL level to predict subclinical atherosclerosis in patients with psoriatic arthritis? Advances in rheumatology (London, England). 2019;59(1):49. [DOI:10.1186/s42358-019-0096-2]

26. Oguntola SO, Hassan MO, Duarte R, Dix-Peek T, Dickens C, Olorunfemi G, et al. Atherosclerotic vascular disease and its correlates in stable black South African kidney transplant recipients. International journal of nephrology and renovascular disease. 2018;11:187-93. [DOI:10.2147/IJNRD.S160553]

27. Yu X, Wang L, Zhang W, Ming J, Jia A, Xu S, et al. Fasting triglycerides and glucose index is more suitable for the identification of metabolically unhealthy individuals in the Chinese adult population: A nationwide study. 2019;10(4):1050-8. [DOI:10.1111/jdi.12975]

28. Dobiásová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clinical biochemistry. 2001;34(7):583-8. [DOI:10.1016/S0009-9120(01)00263-6]

29. Akpınar O, Bozkurt A, Acartürk E, Seydaoğlu G. A new index (CHOLINDEX) in detecting coronary artery disease risk. Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology. 2013;13(4):315-9. [DOI:10.5152/akd.2013.098]

30. Olamoyegun MA, Oluyombo R, Asaolu SO. Evaluation of dyslipidemia, lipid ratios, and atherogenic index as cardiovascular risk factors among semi-urban dwellers in Nigeria. Annals of African medicine. 2016;15(4):194-9. [DOI:10.4103/1596-3519.194280]

31. Libby P. The changing landscape of atherosclerosis. Nature. 2021;592(7855):524-33. [DOI:10.1038/s41586-021-03392-8]

32. Nam B-H, Kannel WB, D'Agostino RB. Search for an optimal atherogenic lipid risk profile: from the Framingham Study. The American journal of cardiology. 2006;97(3):372-5. [DOI:10.1016/j.amjcard.2005.08.055]

33. Bierenbaum ML, Reichstein R, Watkins TR. Reducing atherogenic risk in hyperlipemic humans with flax seed supplementation: a preliminary report. Journal of the American College of Nutrition. 1993;12(5):501-4. [DOI:10.1080/07315724.1993.10718342]

34. Saleh-Ghadimi S, Kheirouri S, Golmohammadi A, Moludi J, Jafari-Vayghan H, Alizadeh M. Effect of flaxseed oil supplementation on anthropometric and metabolic indices in patients with coronary artery disease: a double-blinded randomized controlled trial. Journal of Cardiovascular and Thoracic Research. 2019;11(2):152. [DOI:10.15171/jcvtr.2019.26]

35. Vijaimohan K, Jainu M, Sabitha K, Subramaniyam S, Anandhan C, Devi CS. Beneficial effects of alpha linolenic acid rich flaxseed oil on growth performance and hepatic cholesterol metabolism in high fat diet fed rats. Life sciences. 2006;79(5):448-54. [DOI:10.1016/j.lfs.2006.01.025]

36. Wang M, Zhang X-J, Feng K, He C, Li P, Hu Y-J, et al. Dietary α-linolenic acid-rich flaxseed oil prevents against alcoholic hepatic steatosis via ameliorating lipid homeostasis at adipose tissue-liver axis in mice. Scientific Reports. 2016;6(1):26826. [DOI:10.1038/srep26826]

37. Kuang X, Kong Y, Hu X, Li K, Guo X, Liu C, et al. Defatted flaxseed flour improves weight loss and lipid profile in overweight and obese adults: A randomized controlled trial. Food & function. 2020;11(9):8237-47. [DOI:10.1039/D0FO00838A]

38. Park YB, Do K-M, Bok S-H, Lee M-K, Jeong T-S, Choi M-S. Interactive effect of hesperidin and vitamin E supplements on cholesterol metabolism in high cholesterol-fed rats. International Journal for Vitamin and Nutrition Research. 2001;71(1):36-44. [DOI:10.1024/0300-9831.71.1.36]

39. Miwa Y, Yamada M, Sunayama T, Mitsuzumi H, Tsuzaki Y, Chaen H, et al. Effects of glucosyl hesperidin on serum lipids in hyperlipidemic subjects: preferential reduction in elevated serum triglyceride level. Journal of nutritional science and vitaminology. 2004;50(3):211-8. [DOI:10.3177/jnsv.50.211]

40. Mohammadi M, Ramezani‐Jolfaie N, Lorzadeh E, Khoshbakht Y, Salehi‐Abargouei A. Hesperidin, a major flavonoid in orange juice, might not affect lipid profile and blood pressure: A systematic review and meta‐analysis of randomized controlled clinical trials. Phytotherapy Research. 2019;33(3):534-45. [DOI:10.1002/ptr.6264]

41. Zheng L, Sun A, Han S, Qi R, Wang R, Gong X, et al. Association between visceral obesity and 10-year risk of first atherosclerotic cardiovascular diseases events among American adults: National Health and Nutrition Examination Survey. Frontiers in Cardiovascular Medicine. 2023;10:1249401. [DOI:10.3389/fcvm.2023.1249401]

42. Yari Z, Rahimlou M, Poustchi H, Hekmatdoost A. Flaxseed supplementation improves anthropometric measurements, metabolic, and inflammatory biomarkers in overweight and obese adults. International Journal for Vitamin and Nutrition Research. 2019.

43. Park JB, Velasquez MT. Potential effects of lignan-enriched flaxseed powder on bodyweight, visceral fat, lipid profile, and blood pressure in rats. Fitoterapia. 2012;83(5):941-6. [DOI:10.1016/j.fitote.2012.04.010]

44. Baranowski M, Enns J, Blewett H, Yakandawala U, Zahradka P, Taylor CG. Dietary flaxseed oil reduces adipocyte size, adipose monocyte chemoattractant protein-1 levels and T-cell infiltration in obese, insulin-resistant rats. Cytokine. 2012;59(2):382-91. [DOI:10.1016/j.cyto.2012.04.004]

45. Dayib M, Larson J, Slavin J. Dietary fibers reduce obesity-related disorders: mechanisms of action. Current Opinion in Clinical Nutrition & Metabolic Care. 2020;23(6):445-50. [DOI:10.1097/MCO.0000000000000696]